Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Cornea and External Disease > Common Uveitis Drugs Found Equally Effective
  • Cornea and External Disease

Common Uveitis Drugs Found Equally Effective

Ophthalmology 360
Common Uveitis Drugs Found Equally Effective

Noninfectious uveitis is often treated with oral corticosteroids that present serious side effects after continued use, forcing patients to switch to other drugs. Researchers examined which of those other drugs are most effective post corticosteroid use.

Researchers randomly assigned 216 patients with uveitis to receive methotrexate or mycophenolate. Over 6 months, participants reduced their prednisone to ≤7.5 mg/day and received either 3 g of mycophenolate daily or 25 mg of methotrexate weekly. Treatments were assessed using eye examinations and imaging.

Results showed that mycophenolate and methotrexate were similarly effective: 57% versus 67% experienced controlled inflammation, respectfully. At 6 months, 74% of participants in the methotrexate group had control over uveitis versus 55% in the mycophenolate group. If participants did not experience controlled inflammation, they switched drugs. At 1 year, 69% of participants who switched from mycophenolate to methotrexate experienced controlled inflammation versus only 35% of those who switched from methotrexate to mycophenolate.

Researchers hope these findings will aid in treatment guidance.

You can read more here.

Share

Related Content

  • Cornea and External Disease

Quiz: The impact of blepharitis and conjunctivitis on quality of life

  • Cornea and External Disease

Phase 3 trial of cenegermin-bkbj for PCED enrolls first US patient

  • Cornea and External Disease

Cornea specialists identify key clinical signs linked to microbial keratitis subtypes

Cornea Update: Corneal Dystrophies & Related Conditions with an Update on Genetic Assessment and Treatment
  • Cornea and External Disease

Preventing complications of superficial keratectomy

  • Conference Roundup

Phase 1/2 CLARA study shows AURN001 improves BCVA compared with standard of care for corneal endothelial dysfunction

  • Conference Roundup

Epioxa crosslinking system has positive outcomes at 30 months in patients with keratoconus

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon